The authors state that they adhere with COPE guidelines on publishing ethics as described elsewhere at https://publicationethics.org/. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

In the title compound, C12H14N4O2, the benzimidazole ring is almost planar (r.m.s. deviation = 0.03 Å), with the fused ring system slightly folded at the shared atoms, with a dihedral angle of 3.4 (1)°. The oxazolidinone ring displays a twisted conformation on the –CH2–CH2– bond and its mean plane makes a dihedral angle of 57.4 (1)° with the benzimidazole ring mean plane. In the crystal, molecules are linked by N—H...O and N—H...N hydrogen bonds, forming chains propagating along thea-axis direction. The chains are linked by C—H...O and C—H...N hydrogen bonds, forming a three-dimensional structure, which is reinforced by C—H...π interactions.

3-[2-(1H-Benzimidazol-2-ylsulfanyl)-ethyl]-1,3-oxazolidin-2-one (OXB1) is a new Benzimidazole derivative which was synthesized in our laboratory then characterized with several physicochemical techniques. However, its related toxic effect remains unknown. The present work aims to study its acute toxicity in normal Wistar rats. Six groups of rats received an intrapéritonéale (i.p.) injection of different doses of OXB1 (500, 700, 900, 1000 and 1200mg/kg) and were daily monitored for 14 days. Mortalities, changes in food and water uptake, behavioral changes and weight were monitored. The OXB1 Lethal Dose 50 (LD50) was 1084mg/kg. The administration of the studied molecule at a dose of 900mg/kg did not affect animal viability and body weight (bw). In addition, food and water intake are unchanged. Furthermore, at the this dose, the levels of hematological and biochemical values and organ’s weights were not affected which confirm that the No-Observed-Adverse-Effect Level (NOAEL) dose of OXB1 is 900 mg/kg in normal Wistar rats and could possibly be tested after further analysis in a preliminary clinical test.

No abstract

No abstract